Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T13:40:35.147Z.
Calculation as of: 2026-10-06T13:40:35.147Z.
Quote observation: 2026-10-06T13:39:54.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6ac0f7718e38414e938d0d293bbdd3741326646c7ebae4135e2c8e12d98e3a9c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$986.21M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01B
Price/OCF Ratio
N/A
TTM Avg
517.11
3Y Avg
517.11
5Y Avg
517.11
Market Cap
$1.02B
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.05B
Price/OCF Ratio
12.25
TTM Avg
14.48
3Y Avg
14.58
5Y Avg
15.53
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aktis Oncology, Inc. (AKTS) | $986.86M | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $986.21M | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $1.01B | N/A | N/A | N/A | N/A |
| Janux Therapeutics, Inc. (JANX)vs › | $1.01B | N/A | 517.11 | 517.11 | 517.11 |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.02B | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $949.71M | N/A | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.03B | N/A | 78.34 | 28.91 | 23.78 |
| Kura Oncology, Inc. (KURA)vs › | $940.12M | N/A | 6.63 | 6.62 | 6.62 |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.05B | 12.25 | 14.48 | 14.58 | 15.53 |
| Teladoc Health, Inc. (TDOC)vs › | $1.05B | 4.03 | 4.24 | 5.55 | 12.42 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
